CAMBRIDGE, England--(BUSINESS WIRE)--Bactevo Ltd. announced today that it has entered into a drug discovery collaboration agreement with Boehringer Ingelheim to identify novel small molecule lead compounds. This collaboration leverages Bactevo’s revolutionary TIME (Totally Integrated Medicines Engine) platform, incorporating its ground-breaking synthetic chemistry technology, designed specifically to combine medicinally-relevant ‘tagless’ chemical diversity with ultra-fast phenotypic or molecular target screening in human samples, to further enhance speed, efficiency and quality in identifying novel in vivo enabled leads for undisclosed Boehringer Ingelheim programs of interest.
Under the terms of this multi-program agreement, Bactevo will receive upfront payments and research funding, and be eligible for additional research, development and commercialization milestone payments.
David Williams, Bactevo CEO commented: “We are pleased to be commencing this highly complementary collaboration with Boehringer Ingelheim. It combines our cutting-edge TIME drug discovery platform with the powerful therapeutic drug development and commercialization experience at Boehringer Ingelheim to create much needed new medicines in areas outside of our current therapeutic focus.”
About Bactevo
Bactevo has built a unique, game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Enabled by advance machine learning, TIME utilises its paradigm shift in the speed, efficiency and quality of drug discovery, as well as dramatically enhanced safety profiling, to improve clinical success. In addition to working with partners to develop novel first-in-class medicines, Bactevo is developing breakthrough medicines for the treatment of diseases that involve defects in mitochondrial function, such as MELAS and LHON, as well as diseases of the central nervous system, such as Parkinson’s, Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS). Further information can be found at www.bactevo.com.
